| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.18 | 9e-07 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.17 | 1e-06 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | -0.23 | 1e-05 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-05 |
| mRNA | BMS-345541 | GDSC1000 | pan-cancer | AAC | -0.15 | 3e-05 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.14 | 4e-05 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | -0.15 | 6e-05 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.26 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0001 |